-
公开(公告)号：US20240299416A1
公开(公告)日：2024-09-12
申请号：US18655576
申请日：2024-05-06
Applicant: ReveraGen BioPharma, Inc.
Inventor： Jesse DAMSKER , Eric HOFFMAN
IPC: A61K31/573 , A61K9/00 , A61K9/10 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/38 , A61P21/00 , A61P43/00
CPC classification number: A61K31/573 , A61K9/0053 , A61K9/10 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/26 , A61K47/36 , A61K47/38 , A61P21/00 , A61P43/00
Abstract: The present disclosure provides methods of treating or reducing the symptoms of muscular dystrophy in a human patient between the age of 1 day and 18 years old, comprising administering to the human patient in need thereof a therapeutically effective amount of a vamorolone and/or a salt thereof.
-
公开(公告)号：US10857161B2
公开(公告)日：2020-12-08
申请号：US16226061
申请日：2018-12-19
Applicant: ReveraGen BioPharma, Inc.
Inventor： John M. McCall , Eric Hoffman , Kanneboyina Nagaraju
IPC: A61K31/573 , A61K31/57 , C07J5/00 , A61K31/575
Abstract: Provided herein is a pharmaceutical composition comprising a compound having the structural formula wherein the compound is present in an amount effective to treat or reduce the symptoms of muscular dystrophy. The therapeutically effective amount may be between 10 mg to 200 mg, or may be between 0.01 mg/kg to 10.0 mg/kg. Also provided are methods of treating or reducing the symptoms of muscular dystrophy, comprising the administration, to a patient in need thereof, of a therapeutically effective of the above compound.
-
公开(公告)号：US10000525B2
公开(公告)日：2018-06-19
申请号：US14939717
申请日：2015-11-12
Applicant: ReveraGen Biopharma, Inc
Inventor： John M. McCall , Eric Hoffman , Kanneboyina Nagaraju
IPC: A61K31/56 , C07J9/00 , A61K31/575 , C07J5/00 , A61K31/573 , A61K45/06 , C07J7/00 , C07J13/00 , C07J21/00 , C07J51/00
CPC classification number: C07J9/005 , A61K31/573 , A61K31/575 , A61K45/06 , C07J5/003 , C07J5/0038 , C07J5/0053 , C07J5/0069 , C07J5/0076 , C07J7/008 , C07J9/00 , C07J13/005 , C07J21/00 , C07J51/00 , Y02A50/479
Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
-
公开(公告)号：US11690853B2
公开(公告)日：2023-07-04
申请号：US17008237
申请日：2020-08-31
Applicant: ReveraGen BioPharma, Inc.
Inventor： John M. McCall , Eric Hoffman , Kanneboyina Nagaraju , Jesse Damsker
IPC: A61K31/57
CPC classification number: A61K31/57
Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
-
公开(公告)号：US11382922B2
公开(公告)日：2022-07-12
申请号：US16811973
申请日：2020-03-06
Applicant: ReveraGen BioPharma, Inc.
Inventor： John McCall , Jesse Damsker
IPC: A61K31/573 , A61K9/00 , A61K47/10 , A61K47/36 , A61K9/08
Abstract: Provided is an aqueous oral pharmaceutical suspension composition comprising vamorolone Form I. Also provided are methods for its preparation and its use.
-
Patent Agency Ranking
公开(公告)号：US20210052606A1
公开(公告)日：2021-02-25
申请号：US17082521
申请日：2020-10-28
Applicant: ReveraGen BioPharma, Inc.
Inventor： John M. MCCALL , Eric HOFFMAN , Kanneboyina NAGARAJU
IPC: A61K31/573 , A61K31/575 , C07J5/00 , A61K31/57
Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
-
公开(公告)号：US10799514B2
公开(公告)日：2020-10-13
申请号：US15197118
申请日：2016-06-29
Applicant: Reveragen Biopharma, Inc.
Inventor： John M. McCall , Eric Hoffman , Kanneboyina Nagaraju , Jesse Damsker
IPC: A61K31/57
Abstract: The present invention relates to compounds and methods which may be useful as treatments of diseases.
-
公开(公告)号：US09649320B2
公开(公告)日：2017-05-16
申请号：US15229947
申请日：2016-08-05
Applicant: ReveraGen Biopharma, Inc.
Inventor： John M. McCall , Eric Hoffman , Kanneboyina Nagaraju
IPC: A61K31/57 , C07J5/00 , A61K31/573
CPC classification number: A61K31/573 , A61K31/57 , A61K31/575 , C07J5/0038 , C07J5/0053 , C07J5/0076 , Y02A50/479 , Y10S514/825 , Y10S514/826 , Y10S514/903
Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
-
公开(公告)号：US20240285650A1
公开(公告)日：2024-08-29
申请号：US18496122
申请日：2023-10-27
Applicant: ReveraGen BioPharma, Inc.
Inventor： John M. MCCALL , Eric HOFFMAN , Kanneboyina NAGARAJU
IPC: A61K31/573 , A61K31/57 , A61K31/575 , A61P1/04 , A61P1/16 , A61P3/00 , C07J5/00
CPC classification number: A61K31/573 , A61K31/57 , A61K31/575 , A61P1/04 , A61P1/16 , A61P3/00 , C07J5/0038 , C07J5/0053 , C07J5/0076 , Y02A50/30
Abstract: The present invention relates to compounds and methods which may be useful as treatments of neuromuscular diseases such as muscular dystrophy, and as inhibitors of NF-κB for the treatment or prevention of muscular wasting disease, including muscular dystrophy.
-
公开(公告)号：US20230002439A1
公开(公告)日：2023-01-05
申请号：US17806322
申请日：2022-06-10
Applicant: ReveraGen BioPharma, Inc.
Inventor： John MCCALL , Jesse DAMSKER
IPC: C07J5/00
Abstract: Provided are certain polymorphic forms of vamorolone as well as pharmaceutical compositions and methods for their use.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.018 seconds)
